, Tracking Stock Market Picks
Enter Symbol:
Exelixis, Inc. (EXEL) [hlAlert]

down 10.57 %

Exelixis, Inc. (EXEL) rated Overweight by Piper Jaffray

Posted on: Monday,  Jan 6, 2014  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Exelixis, Inc. (NASDAQ: EXEL) on 01/06/2014, when the stock price was $6.81. Since
then, Exelixis, Inc. has lost 10.57% as of 08/27/2015's recent price of $6.09.
If you would have followed this Piper Jaffray's recommendation on EXEL, you would have lost 10.57% of your investment in 598 days.

Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. Its most advanced pharmaceutical programs focus on drug discovery and development of small molecule drugs for cancer. The Company has nine compounds in clinical development: XL184, XL147, XL765, XL518, XL228, XL019, XL139, XL413 and XL888. Exelixis also has out-licensed to third parties for further development and commercialization of five compounds in preclinical and clinical development: XL880, XL281, XL652, XL550 and FXR Program. The Company has established commercial collaborations with several pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. and GlaxoSmithKline.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/6/2014 8:25 AM Buy
as of 10/17/2014
1 Week up  8.96 %
1 Month down  -7.05 %
3 Months down  -53.93 %
1 YTD down  -76.79 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy